Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Completed · Phase 1/Phase 2

Conditions studied: Diffuse Large B Cell Lymphoma Relapsed, Diffuse Large B Cell Lymphoma Refractory

In brief

This is a Phase 1b/2, open-label, non-randomized multicenter study to assess the safety and efficacy of ibrutinib and lenalidomide in combination with DA-EPOCH-R in subjects with relapsed/refractory Diffuse Large B-cell Lymphoma (DLBCL).

Key facts

Study ID

NCT02142049

Run by

Pharmacyclics LLC.

People needed

35

Starts

2014-05-01

Expected to finish

2017-08-01

Last updated by the study team

2019-02-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• SITE-1 — Duarte, California, United States
• SITE-2 — Los Angeles, California, United States
• SITE-10 — Orange, California, United States
• SITE-3 — Chicago, Illinois, United States
• SITE-5 — Baltimore, Maryland, United States
• SITE-6 — Bethesda, Maryland, United States
• SITE-4 — Ann Arbor, Michigan, United States
• SITE-8 — Albuquerque, New Mexico, United States
• SITE-9 — Stony Brook, New York, United States
• SITE-7 — Charleston, South Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.